In total, 84 (27.4%) samples had original EGFR activating mutations (19del, L858R and other rare mutations) that had been detected in primary tumor specimens before TKI administration, whereas 128 (41.7%) samples exhibited wild-type EGFR (Fig. 2a). This evidence concerns the gene EGFR and neoplasm.